Tables
- TABLE 1
SWOT (strengths, weaknesses, opportunities and threats) analysis: creation of a Tuberculosis (TB) Vaccine Accelerator Council (TB VAC)
Strengths TB VAC will address and proactively tackle the adverse impact of COVID-19 on TB ervices TB VAC encourages global collaboration among funders, global health agencies, the private sector and governments TB VAC is getting high-level support from eminent global health leaders, such as Dr Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization Weaknesses TB VAC will need to find solutions for the complex scientific and technical challenges related to vaccine efficacy, safety and immunological responses TB VAC requires huge resources and adequate funding for successful establishment and day-to-day operation Navigating the time-consuming and challenging regulatory and approval processes for vaccine development can be difficult Achieving sufficient manufacturing capacity and a robust supply chain for TB vaccines can be challenging Inadequate skilled researchers, laboratories and infrastructure may impact progress Access to target populations: the logistics of reaching and vaccinating affected populations, particularly in low-income and middle-income countries could be enormous Opportunities Improved TB prevention: development of effective vaccines to reduce global TB cases including drug-resistant cases and deaths Global health impact: potential to significantly impact global health by accelerating TB vaccine development Threats Insufficient funding: inadequate financial resources could impede the successful establishment and operation of the TB VAC Scientific challenges: overcoming scientific bottlenecks related to vaccine efficacy, safety, and immunological responses
Vol 19 Issue 3
Table of Contents
Ending the TB pandemic: the urgency of a new and improved TB vaccine and the World Health Organization's TB Vaccine Accelerator Council
Jump To
- Article
- Abstract
- Tweetable abstract
- Introduction
- Why is a TB Vaccine Accelerator Council necessary?
- History of TB vaccine development: recent advances, successes and failures
- Adapting lessons from the COVID-19 pandemic for TB vaccine development
- Innovative pathways: advancing TB vaccine development and equitable access for low- and middle-income countries
- Footnotes
- References
- Figures & Data
- Info & Metrics